CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $21.21M, above the global median of $16.24M
- FinancialsAltman Z-Score 2.99: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
337.13MUSDvs all stocks (USD)
Revenue (TTM)
514.70MUSDvs all stocks (USD)
Beta
1.33xvs all stocks
52-Week Change
-42.54%vs all stocks
Market Capitalization
337.13MUSDvs all stocks (USD)
Enterprise Value
459.84MUSDvs all stocks (USD)
Forward P/E
-9.71xPrice to Sales (TTM)
0.6675xPrice to Book (MRQ)
1.40xEnterprise to Revenue
0.8930xEnterprise to EBITDA
12.77xGross Margin
28.90%Operating Margin
-174.69%Return on Assets (TTM)
2.12%Return on Equity (TTM)
0.73%Revenue (TTM)
514.70MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.05USDUpdated Jul 19, 2026Quarterly Revenue Growth
-57.10%Gross Profit (TTM)
380.31MUSDvs all stocks (USD)
EBITDA (TTM)
93.98MUSDvs all stocks (USD)
Net Income (TTM)
-14.55MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-58.19%Operating Cash Flow (TTM)
30.75MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
21.21MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
563.03MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
137.52MUSDFY2025 · Dec 31, 2025Gross Profit
425.51MUSDFY2025 · Dec 31, 2025Operating Income
55.87MUSDvs all stocks (USD)
Pre-tax Income
46.97MUSDFY2025 · Dec 31, 2025Income Tax Expense
9.94MUSDFY2025 · Dec 31, 2025Net Income
37.03MUSDFY2025 · Dec 31, 2025EBIT
55.87MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
93.98MUSDFY2025 · Dec 31, 2025Research & Development
44.54MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
326.24MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-1.14MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.28MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.1600USDFY2025 · Dec 31, 2025EPS (Diluted)
0.1500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
126.74MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
126.74MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
37.03MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
6.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-40.08MUSDFY2025 · Dec 31, 2025Free Cash Flow
-54.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
94.33MUSDFY2025 · Dec 31, 2025Income Tax Paid
5.35MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
37.03MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
26.94MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
9.50MUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
15.73MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-115.80MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-528.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-26.25MUSDFY2025 · Dec 31, 2025Capital Expenditures
-14.15MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-14.15MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.17MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-16.35MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.52MUSDFY2025 · Dec 31, 2025Shares Outstanding
128.67MSharesUpdated Jul 19, 2026Float Shares
57.38MSharesUpdated Jul 19, 2026Shares Short
13.80MSharesUpdated Jul 19, 2026Short Ratio
16.86daysvs all stocks
Short % of Shares Outstanding
16.87%vs all stocks
% Held by Insiders
47.46%vs all stocks
% Held by Institutions
49.50%vs all stocks
Total Cash (MRQ)
91.38MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7100USDUpdated Jul 19, 2026Total Debt (MRQ)
70.86MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1858xCurrent Ratio (MRQ)
3.53xBook Value per Share (MRQ)
1.90USDUpdated Jul 19, 2026Total Assets
598.73MUSDvs all stocks (USD)
Total Current Assets
362.19MUSDFY2025 · Dec 31, 2025Total Liabilities
164.81MUSDFY2025 · Dec 31, 2025Total Non-current Assets
236.54MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
64.69MUSDFY2025 · Dec 31, 2025Total Current Liabilities
100.12MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.68MUSDFY2025 · Dec 31, 2025Accounts Receivable
217.45MUSDFY2025 · Dec 31, 2025Inventory
29.63MUSDFY2025 · Dec 31, 2025Accounts Payable
31.95MUSDFY2025 · Dec 31, 2025Short-term Debt
18.64MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.86MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.26MUSDFY2025 · Dec 31, 2025Long-term Debt
63.49MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.19MUSDFY2025 · Dec 31, 2025Common Stock (Book)
13.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-3.08MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
433.92MUSDvs all stocks (USD)
52-Week Low
2.04USDUpdated Jul 19, 202652-Week High
7.08USDUpdated Jul 19, 202652-Week Change
-42.54%vs all stocks
Beta
1.33xvs all stocks
50-Day MA
2.46USDUpdated Jul 19, 2026200-Day MA
3.54USDUpdated Jul 19, 2026Avg 10-Day Volume
817.05KSharesUpdated Jul 19, 2026Avg 30-Day Volume
801.39KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.1200USDUpdated Jul 19, 2026Other Income / Expense
-11.18MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.99: safe zoneNotable
Altman Z-Score: 2.99
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $21.21M, above the global median of $16.24MNotable
Levered free cash flow (USD): 21,209,000Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule